ASL deficiency: pervasive genetic interactions between active site alleles restore near wildtype function



Michelle Tang¹, Gareth A. Cromie¹, Russell S. Lo¹, Martin S. Timour¹, Hiroki Morizono^{2,3}, Ljubica Caldovic^{2,3}, Nicholas Ah Mew^{2,3}, Andrea Gropman^{2,3,4,5}, <u>Aimée M. Dudley¹</u>

¹Pacific Northwest Research Institute, Seattle, WA, USA, ²Center for Genetic Medicine Research Institute, Children's National Hospital, Washington, DC, USA, ³Department of Genomics and Precision Medicine, School of Medicine and Health Sciences, The George Washington, DC, USA, ⁴Department of Neurology, Division of Neurogenetics and Neurodevelopmental Disabilities, Children's National Hospital, Washington, DC, USA, ⁵Center for Neuroscience Research, Children's National Research Institute, Children's National Hospital, Washington, DC, USA

Argininosuccinate lyase deficiency

Argininosuccinate lyase (ASL) deficiency is the second most common urea cycle disorder (UCD), affecting ~1 in 70,000 live births and accounting for up to 20% of UCD cases. Deficiency in the ASL enzyme results in hyperammonemia, the buildup of blood ammonia to levels toxic to the brain, which can lead to lethargy, seizures, coma and even death. Complications may include neurocognitive deficiency and progressive liver damage. Disease severity ranges from mild to severe depending on level of enzyme activity, and the onset of ASL deficiency can occur in the neonatal period or at later stages of life. Clinical and genetic heterogeneity is further confounded by the phenomenon of intragenic complementation, in which the combination of two variants of the same protein have activity significantly greater than what is expected based on each allele's individual activity. To gain a better understanding of disease manifestation and genotype-phenotype correlation in ASL deficiency, we developed and performed high throughput yeast assays to assess the functional impact of all single nucleotide variant (SNV)-accessible ASL missense variants.

Genetic interactions of compound heterozygotes

Yeast mating of variant strains permits the detection of genetic interactions between different ASL alleles. We tested ~5,400 unique combinations of amorphic missense variants that individually exhibited no ASL activity.



High throughput yeast growth assays for determining variant effects in ASL

The assay leverages the ability of human ASL to functionally replace deletion of its yeast ortholog, ARG4, allowing yeast strains to grow on argininedeficient medium. The growth of yeast cells harboring ASL variants as the sole source of the enzyme provides a quantitative readout of variant enzyme function expressed on an intuitive scale.





Of the \sim 3,600 unique combinations that involve variants of active site residues, over half (~2,200) exhibited strong intragenic complementation, in which the combination of two amorphic variants produced near wildtype levels of activity.



Intragenic complementation occurs frequently between amino acid positions within the active sites and is largely independent of the amino acid substitution.

A representative example with His160, a residue in the catalytic center of ASL, is shown below. Intragenic complementation was observed between every SNVaccessible variant of His160 and the same set of active site variants in our library.









Position in active sites determine intragenic complementation

Schematic of the ASL tetramer assembly Wildtype active sites are indicated by dashed circles Clustering acid positions amino **O**T corresponds to the three interfaces that

Mechanism of intragenic complementation in ASL



PDB=1AOS, ligand=AS (orange stick) Tested amino acid positions colored based on interaction clusters

make up the active site. Intragenic complementation between occurs variants of amino acid positions from different interfaces of the monomer. Depending on the configuration of the ASL variant monomers in a compound heterozygote, the hetero-tetramer may have zero or two wild-type active sites.

> Scan to view a video of the two tetramer configurations on the right.

Variant B Variant A







2 wild-type active sites

Acknowledgements

This work was funded by NIH/NIGMS award R01 GM134274 to A.D. and by the University of Washington Genome Sciences Training Grant 5T32HG000035-27 to M.T.

